Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), results from a ulmination of events that lead to chronic inflammation in the intestine – genetic predisposition, changes in the mucosal immune system, and environmental factors – with a variety of different phenotypes in both UC and CD. Current medical therapies require frequent, and potentially risky, interventions to effectively treat these disorders in an effort to prevent surgical interventions. There are important factors that influence the pharmacokinetics of these treatments, and not all treatments are approved for treating both UC and CD. Furthermore, many patients lose response to monoclonal antibody therapy and physicians must understand the best course of action when this occurs. Current advances in understanding the pathophysiologic mechanisms of IBD have presented novel treatment targets and treatment options, such that patients with refractory IBD may have potential alternative therapy options, and individualizing IBD therapy may become an attainable goal in the near future.
In this interactive symposium, gastroenterology experts will review the disease course of IBD (including the ability to predict disease course and the impact of current therapies) and current strategies for optimizing therapy for refractory IBD with current medical therapies, including limitations/safety issues. The faculty will then discuss our current understanding of the pathophysiology of IBD (the microbiome, genetics, inflammatory and immunology pathophysiology) and the novel treatment options that are becoming available and that are under investigation (biologics, non-biologic anti-inflammatory agents, microbiome- and genetic-based therapies). Interactive case studies will also be used to illustrate how our understanding of the pathophysiology of IBD and these new and emerging therapy options can be applied in clinical settings.
The goal of this activity is to provide gastroenterologists and other primary healthcare providers who treat and manage patients with IBD with the most up-to-date clinical and scientific information on IBD therapies to translate evidence on current and emerging treatment options for IBD into
This activity is designed for gastroenterologists and other primary providers of care for patients with IBD. No prerequisites required.
After participating in this activity, the participant will demonstrate the ability to:
- IDENTIFY current treatment options for patients with refractory IBD and their limitations.
- RECOGNIZE recent advances regarding the pathophysiology of IBD as they relate to treatment.
- DESCRIBE novel treatment paradigms and options for patients with refractory moderate to severe IBD.
- Disease Course of Inflammatory Bowel
- Optimizing Therapy for Refractory IBD
with Current Medical Therapies
- Pathophysiology of IBD and Novel
Gary R. Lichtenstein, MD (Course Director)
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
of the University of Pennsylvania
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
David T. Rubin, MD, AGAF
The Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology, and Nutrition
Co-Director, Digestive Diseases Center
The University of Chicago Medicine
Asher A. Kornbluth, MD
Clinical Professor of Medicine
Clinical Research Director, the Sanford J. Grossman Integrative Center for the Study of IBD
The Inflammatory Bowel Disease Center
The Henry D. Janowitz Division of Gastroenterology
Mount Sinai School of Medicine
New York, New York
The AGA Institute fully complies with the legal requirements of the ADA and the
rules and regulations thereof. Please notify us if you have any special needs.
There is no fee for this educational activity.
Please note: This archive is for reference only; no CE is offered for this activity.